Seeking Alpha

NeoStem: Safety board recommends continuing heart-drug trial

  • NeoStem (NBS +2.2%) say that the Data Safety Monitoring Board for the Phase II trial of its AMR-001 drug has recommended continuing the study following a third interim data and safety review.
  • AMR-001 is being tested for its ability to preserve heart function after a severe heart attack, with the trial comprising 160 patients. (PR)
Comments (2)
  • dcmjboston
    , contributor
    Comment (1) | Send Message
    Over 10% drop yesterday, pretty good recovery today, and the only news anyone following this had to say on NBS was a rumor yesterday and the terse statement above?
    17 Sep 2013, 09:52 PM Reply Like
  • holborn
    , contributor
    Comments (38) | Send Message
    Probio is a trader he gains money with his rumour
    18 Sep 2013, 01:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: